CN Patent

CN103819469A — 一种达沙替尼的晶型及其制备方法

Assigned to Chongqing Pharmaceutical Research Institute Co Ltd · Expires 2014-05-28 · 12y expired

What this patent protects

本发明涉及一种达沙替尼的晶型及其制备方法，达沙替尼晶型A的X-射线粉末衍射图谱在2θ值约为6.4°、9.6°、10.4°、13.0°、16.0°、18.5°、18.8°、22.4°、25.3°、26.7°的位置对应有特征衍射峰，以及含有这种新晶型A的药物组合物及其在肿瘤治疗方面的应用。

USPTO Abstract

本发明涉及一种达沙替尼的晶型及其制备方法，达沙替尼晶型A的X-射线粉末衍射图谱在2θ值约为6.4°、9.6°、10.4°、13.0°、16.0°、18.5°、18.8°、22.4°、25.3°、26.7°的位置对应有特征衍射峰，以及含有这种新晶型A的药物组合物及其在肿瘤治疗方面的应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN103819469A
Jurisdiction
CN
Classification
—
Expires
2014-05-28
Drug substance claim
No
Drug product claim
No
Assignee
Chongqing Pharmaceutical Research Institute Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.